GlassScriptPhysician profile
Oussama Moussan
NPI 1467426171
$1,490.60
in general payments reported to CMS, 2019-2025
17 companies · $941 in 2025
The $941 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.74 · 2021: $129 · 2022: $159 · 2024: $174 · 2025: $941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,088 · Education: $27.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,087.78 |
| Education | $27.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $457.83 | 2022-2025 | |
| Janssen Biotech, INC. | $190.43 | 2025 | Tremfya |
| Phathom Pharmaceuticals, INC. | $168.58 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $163.78 | 2024-2025 | Entyvio, Eohilia |
| E.R. Squibb & Sons, L.L.C. | $118.17 | 2021 | |
| Lilly USA, LLC | $89.19 | 2024-2025 | Omvoh |
| Boston Scientific Corporation | $87.74 | 2019 | |
| Madrigal Pharmaceuticals | $36.86 | 2025 | Rezdiffra |
| Pfizer INC. | $31.53 | 2025 | |
| Celltrion USA INC. | $27.21 | 2024 | Zymfentra |
| Ipsen Biopharmaceuticals, INC | $24.64 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $24.56 | 2024 | Dificid |
| Ardelyx, INC. | $23.38 | 2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $17.89 | 2025 | |
| Novo Nordisk INC | $17.71 | 2025 | Wegovy |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $11.10 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$32,464.18 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oussama Moussan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.